Actively Recruiting
Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
Led by University Hospital, Geneva · Updated on 2024-12-06
220
Participants Needed
18
Research Sites
217 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Geneva
Lead Sponsor
S
Swiss National Science Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate two treatment strategies in patients with chronic atrial fibrillation and heart failure, who are eligible for atrial fibrillation ablation. Patients will be randomized to either atrial fibrillation ablation or to implantation of a pacemaker with conduction system pacing followed by atrioventricular node ablation. The effect of treatment allocation on total mortality, cardiovascular hospitalization and heart failure hospitalization will be compared.
CONDITIONS
Official Title
Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Persistent atrial fibrillation with symptomatic heart failure despite medical therapy, suitable for atrial fibrillation ablation, with at most one previous pulmonary vein isolation procedure
- At least one hospital admission or emergency room/heart failure clinic visit for heart failure in the past 2 years with NT-pro-BNP > 1000 pg/ml or BNP > 250 pg/ml measured during this period
- Previous or current treatment with rate or rhythm control drugs
- Age over 60 years
You will not qualify if you...
- New York Heart Association (NYHA) Class IV and systolic blood pressure ≤80 mmHg despite optimized therapy
- Life expectancy less than 2 years
- Need for major surgical intervention
- Myocardial infarction, stroke, or percutaneous coronary intervention within the previous 3 months
- Previously implanted or planned implantation of cardiac resynchronization therapy device or pacemaker (implantable cardioverter defibrillator implantation without pacing indication is allowed)
- Participation in another controlled trial
- Inability to sign an informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
St Elisabeth sister's Hospital
Graz, Austria
Not Yet Recruiting
2
Antwerp University Hospital
Antwerp, Belgium
Not Yet Recruiting
3
Acibadem City Clinic Tokuda University Hospital
Sofia, Bulgaria
Not Yet Recruiting
4
University Hospital, Kralovske Vinohrady
Prague, Czechia
Not Yet Recruiting
5
Heart and Lung Center, University of Helsinki
Helsinki, Finland
Actively Recruiting
6
Hôpital Charles Nicolle
Rouen, France
Not Yet Recruiting
7
Herzzentrum Leipzig
Leipzig, Germany
Not Yet Recruiting
8
Semmelweis University
Budapest, Hungary
Not Yet Recruiting
9
Bologna University Hospital
Bologna, Italy
Not Yet Recruiting
10
University Hospital Maastricht
Maastricht, Netherlands
Not Yet Recruiting
11
Jagiellonian University
Krakow, Poland
Not Yet Recruiting
12
Hospital Universitario La Paz
Madrid, Spain
Not Yet Recruiting
13
Hospital Universitario y Politecnico La Fe
Madrid, Spain
Not Yet Recruiting
14
University Hospital Geneva
Geneva, Canton of Geneva, Switzerland, 1211
Actively Recruiting
15
University Hospital of Basel
Basel, Switzerland
Actively Recruiting
16
Inselspital
Bern, Switzerland
Actively Recruiting
17
University Hospital of Zurich
Zurich, Switzerland
Actively Recruiting
18
National Heart and Lung Institute, Imperial College London
London, United Kingdom
Not Yet Recruiting
Research Team
H
Haran Burri
CONTACT
N
Nikola Kozhuharov
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here